Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

AbbVie Science Chief to Retire With No Successor in Place

Don't Miss Out —
Follow us on:

May 10 (Bloomberg) -- AbbVie Inc.’s long-time head of research will retire from the drugmaker, leaving the newly spun off company without a leader for its efforts to develop new medicines and buttress its future prospects.

Chief Scientific Officer John Leonard, 55, will retire in the next few months, North Chicago, Illinois-based AbbVie said today in regulatory filing. The company didn’t name a successor to Leonard, who has been with AbbVie and its parent, Abbott Laboratories for about 21 years.

The drug company has been trying to diversify its products past Humira, a rheumatoid arthritis injection that sold $9.27 billion last year and made up 50 percent of sales. One top product, a kidney drug called bardoxolone methyl, failed in final-stage clinical trials last year. Another treatment for the viral infection hepatitis C is in the last stage of testing.

Leonard “will be involved in the transition process for naming his successor,” the company said in the filing. AbbVie split from Abbott at the beginning of this year in a move to let each company focus on its core product lines of drugs and medical devices, respectively.

Jennifer Smoter, a spokeswoman for AbbVie, declined to elaborate further on Leonard’s departure. “We will announce future organizational plans at a later date,” she said in an e-mail.

To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net;

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.